Scott M Rocklage - Net Worth and Insider Trading

Scott M Rocklage Net Worth

The estimated net worth of Scott M Rocklage is at least $2 Million dollars as of 2024-04-24. Scott M Rocklage is the Director, 10% Owner of Relypsa Inc and owns about 62,316 shares of Relypsa Inc (RLYP) stock worth over $2 Million. Scott M Rocklage is the Director, 10% Owner of Aprea Therapeutics Inc and owns about 75,965 shares of Aprea Therapeutics Inc (APRE) stock worth over $407,932. Scott M Rocklage is also the Director of Pulmatrix Inc and owns about 844 shares of Pulmatrix Inc (PULM) stock worth over $1,705. Details can be seen in Scott M Rocklage's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Scott M Rocklage has not made any transactions after 2020-06-16 and currently still holds the listed stock(s).

Transaction Summary of Scott M Rocklage

To

Scott M Rocklage Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Scott M Rocklage owns 21 companies in total, including Aprea Therapeutics Inc () , Akouos Inc () , and Cabaletta Bio Inc () among others .

Click here to see the complete history of Scott M Rocklage’s form 4 insider trades.

Insider Ownership Summary of Scott M Rocklage

Ticker Comapny Transaction Date Type of Owner
Aprea Therapeutics Inc 2020-06-30 director
Akouos Inc 2020-06-25 10 percent owner
Cabaletta Bio Inc 2019-10-24 10 percent owner
Arvinas Inc 2018-09-26 10 percent owner
Crinetics Pharmaceuticals Inc 2018-07-17 10 percent owner
IDEAYA Biosciences Inc 2020-11-11 10 percent owner & Former 10% holder
Homology Medicines Inc 2018-03-27 10 percent owner
Cidara Therapeutics Inc 2015-04-14 director & 10 percent owner
scPharmaceuticals Inc 2017-11-16 10 percent owner
Audentes Therapeutics Inc 2017-04-24 other: former 10% owner
PhaseRx Inc 2016-05-17 10 percent owner
Pulmatrix Inc 2016-02-03 director
EPIRUS Biopharmaceuticals Inc 2015-06-05 director & 10 percent owner
Viveve Medical Inc 2014-09-23 10 percent owner
Achaogen Inc 2014-03-11 director
Relypsa Inc 2013-11-20 director & 10 percent owner
IPI Legacy Liquidation Co 2021-04-22 10 percent owner
Entrada Therapeutics Inc 2021-10-28 10 percent owner
Rallybio Corp 2021-07-29 10 percent owner
Pear Therapeutics Inc 2021-12-03 10 percent owner
Skye Bioscience Inc 2023-08-18 10 percent owner

Scott M Rocklage Latest Holdings Summary

Scott M Rocklage currently owns a total of 3 stocks. Among these stocks, Scott M Rocklage owns 62,316 shares of Relypsa Inc (RLYP) as of November 20, 2013, with a value of $2 Million and a weighting of 82.95%. Scott M Rocklage owns 75,965 shares of Aprea Therapeutics Inc (APRE) as of June 16, 2020, with a value of $407,932 and a weighting of 16.98%. Scott M Rocklage also owns 844 shares of Pulmatrix Inc (PULM) as of June 16, 2015, with a value of $1,705 and a weighting of 0.07%.

Latest Holdings of Scott M Rocklage

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
RLYP Relypsa Inc 2013-11-20 62,316 31.99 1,993,489
APRE Aprea Therapeutics Inc 2020-06-16 75,965 5.37 407,932
PULM Pulmatrix Inc 2015-06-16 844 2.02 1,705

Holding Weightings of Scott M Rocklage


Scott M Rocklage Form 4 Trading Tracker

According to the SEC Form 4 filings, Scott M Rocklage has made a total of 0 transactions in Relypsa Inc (RLYP) over the past 5 years. The most-recent trade in Relypsa Inc is the acquisition of 9,364 shares on November 20, 2013, which cost Scott M Rocklage around $103,004.

According to the SEC Form 4 filings, Scott M Rocklage has made a total of 3 transactions in Aprea Therapeutics Inc (APRE) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Aprea Therapeutics Inc is the sale of 120,164 shares on June 16, 2020, which brought Scott M Rocklage around $4 Million.

According to the SEC Form 4 filings, Scott M Rocklage has made a total of 0 transactions in Pulmatrix Inc (PULM) over the past 5 years. The most-recent trade in Pulmatrix Inc is the acquisition of 194 shares on June 16, 2015, which cost Scott M Rocklage around $266,978.

Insider Trading History of Scott M Rocklage

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Scott M Rocklage Trading Performance

GuruFocus tracks the stock performance after each of Scott M Rocklage's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Scott M Rocklage is 134.21%. GuruFocus also compares Scott M Rocklage's trading performance to market benchmark return within the same time period. The performance of stocks bought by Scott M Rocklage within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Scott M Rocklage's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Scott M Rocklage

Average Return

34.48%

Average return per transaction

Outperforming Transactions

67%

2 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 61.05 134.21 33.88 34.48 1.8 -63.27
Relative Return to S&P 500(%) 59.23 133.63 30.83 24.62 -6.3 -73.13

Scott M Rocklage Ownership Network

Ownership Network List of Scott M Rocklage

No Data

Ownership Network Relation of Scott M Rocklage


Scott M Rocklage Owned Company Details

What does Aprea Therapeutics Inc do?

Who are the key executives at Aprea Therapeutics Inc?

Scott M Rocklage is the director of Aprea Therapeutics Inc. Other key executives at Aprea Therapeutics Inc include President & CEO Oren Gilad , SrVP/CFO/Prin. Fin &Acctg. Off John P. Hamill , and director & President & CEO Christian S Schade .

Aprea Therapeutics Inc () Insider Trades Summary

Over the past 18 months, Scott M Rocklage made no insider transaction in Aprea Therapeutics Inc (). Other recent insider transactions involving Aprea Therapeutics Inc () include a net purchase of 16,957 shares made by Bernd R. Seizinger , a net purchase of 6,860 shares made by Henneman John B Iii , and a net purchase of 2,000 shares made by Oren Gilad .

In summary, during the past 3 months, insiders sold 0 shares of Aprea Therapeutics Inc () in total and bought 16,730 shares, with a net purchase of 16,730 shares. During the past 18 months, 0 shares of Aprea Therapeutics Inc () were sold and 26,827 shares were bought by its insiders, resulting in a net purchase of 26,827 shares.

Aprea Therapeutics Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Aprea Therapeutics Inc Insider Transactions

No Available Data

Scott M Rocklage Mailing Address

Above is the net worth, insider trading, and ownership report for Scott M Rocklage. You might contact Scott M Rocklage via mailing address: C/o 5am Ventures, 501 2nd Street, Suite 350, San Francisco Ca 94107.

Discussions on Scott M Rocklage

No discussions yet.